Richard Scott Struthers - 20 Feb 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
20 Feb 2025
Transactions value $
$0
Form type
4
Filing time
24 Feb 2025, 16:30:10 UTC
Previous filing
04 Dec 2024
Next filing
21 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Award $0 +89,000 +35% $0 346,485 20 Feb 2025 Direct F1
holding CRNX Common Stock 570,805 20 Feb 2025 By Family Trust 1
holding CRNX Common Stock 110,000 20 Feb 2025 By Family Trust 2
holding CRNX Common Stock 110,000 20 Feb 2025 By Family Trust 3
holding CRNX Common Stock 100,000 20 Feb 2025 By Family Trust 4
holding CRNX Common Stock 1,000 20 Feb 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Award $0 +313,000 $0 313,000 20 Feb 2025 Common Stock 313,000 $36.86 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026.
F2 The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025.